Company: SHPH
Filing Date: 2025-03-12
Form Type: 8-K
Source: 0001493152-25-009922
Chunk: 0

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-03-12
Form: 8-K
Item: Item 5.02
Chunk 0
---
Item
5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers.

On
March 11, 2025, Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the “ Company”), appointed Mr. Christopher
Cooper to the position of interim co-Chief
Executive Officer (“ Interim Co-CEO”). As
Interim Co-CEO, Mr.
Cooper will work to enhance the Company’s capital markets and business capabilities. Dr. Anatoly Dritschilo, Chairman of the Company’s
Board of Directors, will continue in his role as Co-CEO overseeing
the Company’s scientific and clinical trial activities.